Bayer’s Stivarga OK’d for Colon Cancer
(MedPage Today) -- Regorafenib (Stivarga), an inhibitor of multiple kinase enzymes, has been approved for use in treatment-refractory, metastatic colorectal cancer, the FDA announced Wednesday.
Bayer’s Stivarga OK’d for Colon Cancer
(MedPage Today) — Regorafenib (Stivarga), an inhibitor of multiple kinase enzymes, has been approved for use in treatment-refractory, metastatic colorectal cancer, the FDA announced Thursday.
Article printed from Gastroenterology Education and CPD for trainees and specialists: https://www.gastrotraining.com